Mode
Text Size
Log in / Sign up
N/A N=77 Randomized Basic Science

Role of Slow-wave Activity and Plasticity in MDD

Depression

Enrolled (actual)
77
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcome: Primary: Compare Indices of Net Synaptic Strength (Transcranial Magnetic Stimulation Evoked Potentials) in Individuals With MDD to Healthy Controls — 195.07; 179.16; 323.22; 212.73 millivolts (mV) — p=<0.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
slow-wave disruption (Behavioral)
Age
Adult · 25+ yrs
Sex
All
Sponsor
University of Pennsylvania
Primary completion
Mar 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Compare Indices of Net Synaptic Strength (Transcranial Magnetic Stimulation Evoked Potentials) in Individuals With MDD to Healthy Controls
195.07; 179.16; 323.22; 212.73 <0.05 sig
PRIMARY
Compare Markers Associated With Plasticity (BDNF) in Individuals With MDD to Healthy Controls
1599.80; 1738.32; 2839.79; 2860.74 <0.05 sig
SECONDARY
Determine if Slow-wave Disruption Alters Mood in Individuals With MDD
5.25; 1.44; 5.53; 1.22 <0.001 sig

Summary

The hypothesis underlying this proposal is that deficits of synaptic plasticity underlie the slow-wave activity (SWA) abnormalities observed n major depressive disorder (MDD), and that manipulating SWA may serve to circumvent these deficits by facilitating an increase in synaptic strength via the inhibition of synaptic down-scaling, thereby improving plasticity and mood.

Eligibility Criteria

Inclusion Criteria

  • Age: 25-50
  • Right handed
  • English speaking
  • Normal cognition
  • Normal or corrected-to-normal vision and hearing
  • Current depression as assessed on the SCID and Hamilton Rating Scale for Depression
  • Stable, normally-time sleep-wake cycles as determined by interview, 1-week daily sleep log and 1-week wrist actigraphy evidence

Exclusion Criteria

  • Current or prior medical condition
  • History of stroke, epilepsy, brain aneurysm clip or head injury causing unconsciousness
  • Implanted devices (i.e. aneurysm clip or cardiac pacemaker)
  • Sleep disorders other than insomnia
  • History of bipolar disorder, delirium, dementia, amnestic disorder, schizophrenia and other psychotic disorders
  • No history of depression for the control group.
  • For women, pregnancy will exclude participation.
  • Lifetime history of electroconvulsive therapy
  • travel beyond 2 time zones in the 2 months before study
  • Unwillingness to refrain from using alcohol or caffeine during the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04150718). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search